A predictive probability interim design for phase II clinical trials with continuous endpoints.
Sign Up to like & getrecommendations! Published in 2018 at "Statistics in medicine"
DOI: 10.1002/sim.7659
Abstract: Molecular targeted therapies come often with lower toxicity profiles than traditional cytotoxic treatments, thus shifting drug development paradigm into establishing evidence of biological activity, target modulation, and pharmacodynamics effects of these therapies in early phase… read more here.
Keywords: phase; probability interim; continuous endpoints; predictive probability ... See more keywords